Volume 23 Issue 7
Jul.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(7): 1127-1129
NI Fangfang, LI Yuzhi, LIU Hongli, WANG Lingling. Analysis of prognosis factors and prognosis of cervical cancer[J]. Chinese Journal of General Practice, 2025, 23(7): 1127-1129. doi: 10.16766/j.cnki.issn.1674-4152.004080
Citation: NI Fangfang, LI Yuzhi, LIU Hongli, WANG Lingling. Analysis of prognosis factors and prognosis of cervical cancer[J]. Chinese Journal of General Practice, 2025, 23(7): 1127-1129. doi: 10.16766/j.cnki.issn.1674-4152.004080
shu

Analysis of prognosis factors and prognosis of cervical cancer

doi: 10.16766/j.cnki.issn.1674-4152.004080

  • Department of Obstetrics and Gynecology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 KJ2021A0754

  • Received Date: 2025-02-11
    Available Online: 2025-10-25
    Abstract
  •   Objective  To investigate the prognosis of different substages of stage ⅢC in the new staging system of cervical cancer in FIGO 2018 and its influencing factors affecting the prognosis of stage ⅢC.  Methods  The medical records of patients with stage Ⅰ-Ⅱ radical cervical cancer resection from January 2015 to December 2017 in the First Affiliated Hospital of Bengbu Medical University were collected, and the five-year survival rate and five-year recurrence rate of stage Ⅰ, stage Ⅱ, stage ⅢC-r, stage ⅢC-p, and stage ⅢC-rp after re-staging were compared. Univariate and multivariate analyses were performed on the influencing factors of the prognosis of stage ⅢC patients.  Results  There was no significant difference in the 5-year overall survival rate of cervical cancer between stage ⅢC-r (96.84%) and stage Ⅰ (98.98%) and stage Ⅱ (96.58%, P>0.05), which was contrary to the principle that the higher the stage of cervical cancer, the worse the prognosis. There were significant differences in tumor size, number of metastatic lymph nodes, vaginal vault involvement, location of metastatic lymph nodes, 5-year survival rate and recurrence rate in pathologically confirmed patients with stage ⅢC (ⅢC -p + ⅢC-rp stage, P < 0.05). The influencing factors related to univariate analysis were included in the Cox proportional hazards regression model for data processing, and the results suggested that whether the vaginal vault was involved and the number of lymph nodes metastases were independent risk factors for the prognosis of cervical cancer.  Conclusion  From the perspective of patient prognosis, the 5-year overall survival rate of cervical cancer in FIGO 2018 is comparable to that of stage ⅢC-r and stage Ⅱ, but the oncological outcomes of stage ⅢC-p and stage ⅢC-rp are significantly worse than those of stage ⅢC-r. It is contrary to the principle that the higher the stage of cervical cancer, the worse the prognosis. The prognosis of stage ⅢC patients is quite different, and their survival outcome is affected by factors such as tumor size, vaginal vault involvement, number and location of metastatic lymph nodes, and whether vaginal vault is involved and the number of metastatic lymph nodes are independent risk factors for the prognosis of stage ⅢC cervical cancer.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    BRAY F, FERlAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
    [2]
    刘萍, 黎志强, 柳攀, 等. FIGO 2018宫颈癌分期Ⅲ期各亚期设置合理性探讨[J]. 中国实用妇科与产科杂志, 2021, 37(6): 669-672.

    LIU P, LI Z Q, LIU P, et al. Rationality of stageⅢsubstaging in FIGO 2018 staging of cervical cancer[J]. Chinese Journal of Practical Gynecology and Obstetrics, 2021, 37(6): 669-672.
    [3]
    钟美玲, 杨剑桐, 王亚男, 等. 2018版国际妇产科联盟宫颈癌分期系统ⅢC1期在预后评估中的价值及影响因素分析[J]. 癌症进展, 2022, 20(13): 1338-1341.

    ZHONG M L, YANG J T, WANG Y N, et al. Value and risk factors for the 2018 revised International Federation of Gynecology and Obstetrics staging system for cervical cancer stage ⅢC1 in prognostic evaluation[J]. Oncology Progress, 2022, 20(13): 1338-1341.
    [4]
    YANG E, HUANG S Y, RAN X T, et al. The 5-year overall survival of cervical cancer in stage ⅢC-r was little different to stage Ⅰ and Ⅱ: a retrospective analysis from a single center[J]. BMC Cancer, 2021, 21(1): 203. DOI: 10.1186/s12885-021-07890-w.
    [5]
    胡家琳. FIGO 2018 ⅢC1p期宫颈癌患者的预后分析[D]. 蚌埠: 蚌埠医学院, 2021.

    HU J L. Prognostic analysis of FIGO 2018 stage ⅢC1p cervical cancer patients[D]. Bengbu: Bengbu Medical College, 2021.
    [6]
    李咏, 张璨, 何爱琴, 等. 115例宫颈鳞癌患者的临床病理特点及治疗后生存分析[J]. 东南大学学报(医学版), 2024, 43(1): 71-77.

    LI Y, ZHANG C, HE A Q, et al. Analysis of clinicopathologic characteristics and survival of 115 cases of cervical squamous cell carcinoma[J]. Journal of Southeast University(Medical Science Edition), 2024, 43(1): 71-77.
    [7]
    关星群, 郭保亮, 张辉. CT联合MR成像对宫颈癌盆腔淋巴结转移的诊断价值[J]. 影像研究与医学应用, 2021, 5(19): 208-209, 212.

    GUAN X Q, GUO B L, ZHANG H. The diagnostic value of CT combined with MR imaging for pelvic lymph node metastasis in cervical cancer[J]. Journal of Imaging Research and Medical Applications, 2021, 5(19): 208-209, 212.
    [8]
    NGUYEN N C, BERIWAL S, MOON C H, et al. Diagnostic value of FDG PET/MRI in females with pelvic malignancy: a systematic review of the literature[J]. Front Oncol, 2020, 10: 519440. DOI: 10.3389/fonc.2020.519440.
    [9]
    MATSUO K, MACHIDA H, MANDELBAUM R S, et al. Validation of the 2018 FIGO cervical cancer staging system[J]. Gynecol Oncol, 2019, 152(1): 87-93. doi: 10.1016/j.ygyno.2018.10.026
    [10]
    WRIGHT J D, MATSUO K, HUANG Y M, et al. Prognostic performance of the 2018 international federation of gynecology and obstetrics[J]. Obstet Gynecol, 2019, 134(1): 49-57. doi: 10.1097/AOG.0000000000003311
    [11]
    游会婷, 晋茂生, 刘健. MRI联合CDK4、Ki-67对早期宫颈癌淋巴结转移的预测价值[J]. 中华全科医学, 2024, 22(1): 5-9. doi: 10.16766/j.cnki.issn.1674-4152.003020

    YOU H T, JIN M S, LIU J. Predictive value of MRI combined with CDK4 and Ki-67 for lymph node metastasis in early cervical cancer[J]. Chinese Journal of General Practice, 2024, 22(1): 5-9. doi: 10.16766/j.cnki.issn.1674-4152.003020
    [12]
    AYHAN A, ASLAN K, BULUT A N, et al. Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as IB disease?[J]. Eur J Obstet Gynecol Reprod Biol, 2019, 240: 209-214. doi: 10.1016/j.ejogrb.2019.07.002
    [13]
    GONZALEZ-BENITEZ C, SALAS P, GRABOWSKI J P, et al. Lack of survival benefit of para-aortic lymphadenectomy in advanced cervical cancer[J]. Gynecol Obstet Invest, 2019, 84(4): 407-411. doi: 10.1159/000497350
    [14]
    YAN D D, TANG Q, CHEN J H, et al. Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors[J]. Cancer Manag Res, 2019, 11: 5473-5480. doi: 10.2147/CMAR.S203059
    [15]
    朱敏莹, 官成浓. 宫颈癌腹主动脉旁淋巴结的影像诊断及放射治疗研究进展[J]. 临床医学研究与实践, 2024, 9(6): 194-198.

    ZHU M Y, GUAN C N. Research progress of imaging diagnosis and radiotherapy in para-aortic lymph nodes of cervical cancer[J]. Clinical Research and Practice, 2024, 9(6): 194-198.
    [16]
    LIU X L, WANG W P, HU K, et al. A Risk stratification for patients with cervical cancer in stage ⅢC1 of the 2018 FIGO staging system[J]. Sci Rep, 2020, 10(1): 362. DOI: 10.1038/s41598-019-57202-3.
    [17]
    郭晶晶. 局部晚期宫颈癌根治性同步放化疗的临床疗效及预后影响因素研究[J]. 临床研究, 2023, 31(10): 29-31.

    GUO J J. Clinical efficacy and prognostic factors of radical synchronous radiotherapy and chemotherapy for locally advanced cervical cancer[J]. Clinical Research, 2023, 31(10): 29-31.
    [18]
    赵新月, 胡莉钧. 局部晚期宫颈癌预后影响因素的研究进展[J]. 癌症进展, 2023, 21(15): 1635-1638.

    ZHAO X Y, HU L J. Research progress on prognostic factors of locally advanced cervical cancer[J]. Oncology Progress, 2023, 21(15): 1635-1638.
    [19]
    王芳, 吴珍珍, 关崇丽, 等. 宫颈癌淋巴结转移的危险因素分析及对预后的影响[J]. 中国当代医药, 2023, 30(18): 82-87.

    WANG F, WU Z Z, GUAN C L, et al. Risk factors analysis of lymph node metastasis of cervical cancer and its impact on prognosis evaluation[J]. China Modern Medicine, 2023, 30(18): 82-87.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (17) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return